According to Zacks, “Translate Bio, Inc. operates as a therapeutics company. It develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio, Inc. is based in MA, United States. “
Several other research analysts also recently weighed in on the company. HC Wainwright reaffirmed a buy rating and set a $21.00 target price on shares of Translate Bio in a research note on Tuesday, April 9th. ValuEngine downgraded Translate Bio from a buy rating to a hold rating in a research note on Friday, December 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. Translate Bio has a consensus rating of Buy and an average price target of $22.75.
Translate Bio (NASDAQ:TBIO) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.09. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $0.80 million. On average, sell-side analysts anticipate that Translate Bio will post -1.52 EPS for the current year.
Hedge funds have recently made changes to their positions in the company. Barclays PLC raised its stake in shares of Translate Bio by 82.8% during the 4th quarter. Barclays PLC now owns 6,710 shares of the company’s stock worth $50,000 after buying an additional 3,039 shares during the period. Rhumbline Advisers acquired a new position in shares of Translate Bio during the 4th quarter worth approximately $77,000. Two Sigma Investments LP acquired a new position in shares of Translate Bio during the 4th quarter worth approximately $118,000. Teachers Advisors LLC acquired a new position in shares of Translate Bio during the 3rd quarter worth approximately $126,000. Finally, TIAA CREF Investment Management LLC acquired a new position in shares of Translate Bio during the 3rd quarter worth approximately $137,000. 59.27% of the stock is owned by institutional investors and hedge funds.
Translate Bio Company Profile
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Featured Story: Momentum Indicator: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.